Immuneering Corporation (IMRX) saw its stock price rise by 3.06% to close at $2.02 on January 17th, following the release of promising data from its ongoing Phase 2a trial of IMM-1-104, a therapy for pancreatic cancer. The stock opened at $2.00, reached a high of $2.09, and a low of $1.93, with trading volume at 676,767 shares, which is 33.87% of the average. The positive momentum was driven by the announce
Immuneering Corporation's stock is experiencing a notable increase following the release of promising data from its ongoing Phase 2a trial of IMM-1-104, a therapy for pancreatic cancer. The company reported that the combination of IMM-1-104 with modified gemcitabine/nab-paclitaxel achieved an overall response rate of 43%, significantly surpassing the 23% benchmark from the Phase 3 MPACT study. Additionally,
Immuneering Corporation's stock is experiencing a notable increase following the release of promising data from its ongoing Phase 2a trial of IMM-1-104, a therapy for pancreatic cancer. The company reported that the combination of IMM-1-104 with modified gemcitabine/nab-paclitaxel achieved an overall response rate of 43%, significantly surpassing the 23% benchmark from the Phase 3 MPACT study. Additionally,
Immuneering Corporation (IMRX) saw its stock decline by 2.99% today, closing at $1.95 after opening at $2.07. The stock experienced a high of $2.07 and a low of $1.95, with trading volume reaching 830,349 shares, which is 34.37% of its average volume. Despite announcing a positive update on January 13th from its Phase 2a trial of IMM-1-104 in combination with modified FOLFIRINOX for first-line pancreatic ca
Immuneering Corporation's stock is experiencing a decline today, despite the company announcing a positive update from its Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX for first-line pancreatic cancer. The update, released on January 13, 2025, highlighted two additional partial responses, bringing the overall response rate to 50% among six evaluable patients. This is a significant
Immuneering Corporation's stock is experiencing a decline today, despite the company announcing a positive update from its Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX in first-line pancreatic cancer. The update, released on January 13, 2025, highlighted two additional partial responses, bringing the overall response rate to 50% among evaluable patients, which is significantly hig
Immuneering Corporation (IMRX) saw a positive trading session, closing at $2.07, up 3.50% from the previous close of $2.00. The stock opened at $2.01 and reached an intraday high of $2.18 before settling. The upward movement was supported by a reaffirmation of a "buy" rating from Needham & Company LLC, with a target price of $15.00, as reported on January 10th. This follows a similar "buy" rating from Chard
Immuneering Corporation's stock is experiencing a decline today, which may be attributed to a broader market reassessment following recent positive developments. Despite the reaffirmation of a "buy" rating from Chardan Capital with a $13.00 target price, the stock has not seen a corresponding upward movement. This comes after a previous downgrade by Morgan Stanley on December 13th, which shifted the rating
Immuneering Corporation's stock is experiencing a notable decline today, following a significant surge earlier in the week. On January 7, the company announced positive data updates from its ongoing Phase 2a trial of IMM-1-104, which led to a 58% spike in share price. However, this enthusiasm appears to have waned, as the stock has reversed course, dropping by 15.3% on January 8. The initial excitement was
Immuneering Corporation (IMRX) experienced a significant decline today, closing at $2.00, down 15.25% from the previous close of $2.36. The stock opened at $2.14 and reached a high of $2.26 before dropping to a low of $1.90, with trading volume surging to 4,779,217 shares, more than double the average volume. Despite positive data from the ongoing phase 2a trial of IMM-1-104 in pancreatic cancer, which show
Immuneering Corporation's stock is experiencing a decline today, despite receiving a reaffirmed "buy" rating from Chardan Capital with a price target of $13.00, suggesting a significant potential upside. However, the market seems to be reacting to a broader context of mixed analyst opinions. While Chardan Capital and Needham & Company LLC maintain a positive outlook, Morgan Stanley recently downgraded the s
Immuneering Corporation (IMRX) saw a significant price increase today, closing at $1.84, up 13.58% from the previous close of $1.62. The stock opened at $1.60 and reached an intraday high of $1.86, with trading volume at 508,360 shares, which is 31.05% of the average volume. The upward movement was primarily driven by the announcement of the launch of its Pancreatic Cancer Advisory Board. This development h
Immuneering Corporation's stock is experiencing a notable rise today following the announcement of the launch of its Pancreatic Cancer Advisory Board. This development underscores the clinical progress of their lead candidate, IMM-1-104, which has recently received Orphan Drug designation and Fast Track designations for first- and second-line pancreatic cancer treatments. The establishment of this advisory
Immuneering Corporation (IMRX) is experiencing a notable increase in its stock price, rising 14.18% to $1.95 as of 11:41 AM on November 14, following an opening price of $1.86. The stock has seen a high of $2.17 and a low of $1.85 today, with a trading volume of 1,071,701 shares, which is 19.37% of its average daily volume of 5,531,507 shares. This surge comes after the company reported its third-quarter fi
Immuneering Corporation (IMRX) is experiencing a significant surge in its stock price, up 18.63% to $2.37 as of 1:41 pm on October 15, following the announcement that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its investigational drug IMM-1-104 for the treatment of pancreatic cancer. The stock opened at $2.46 and has seen a high of $2.51 and a low of $2.15 today. The
Immuneering Corporation (IMRX) is experiencing a notable decline in its stock price, down 11.37% to $1.94 as of 1:08 pm on October 14, after opening at $2.17. The stock has reached a high of $2.20 and a low of $1.94 today, with a volume of 605,815 shares traded, which is only 9.61% of its average daily volume of 6,306,257. The decline follows concerns highlighted in a recent analysis about the company's cas
Immuneering Corporation (IMRX) experienced a significant decline today, closing at $2.87, down 10.59% from the previous close of $3.21. The stock opened at $3.13 and reached a high of $3.35 before dropping to a low of $2.85. Despite the lack of specific company news, the stock's movement appears to be influenced by broader market dynamics and speculative trading activity. On social media, particularly on R
Immuneering Corporation (IMRX) is experiencing a significant surge in its stock price, climbing 35.95% to $3.29 as of 12:52 pm on September 20. The stock opened at $2.36 and has reached a high of $3.33, with a substantial trading volume of 13,873,782 shares, far exceeding its average daily volume of 5,722,333. This remarkable increase is largely attributed to a positive outlook from Morgan Stanley, which su
Immuneering Corporation (IMRX) is seeing a notable increase in its stock price, up 10.33% to $2.67 as of 10:07 am on September 20, after opening at $2.36. The stock has reached a high of $2.70 and a low of $2.36 in the early trading hours. Despite being just over half an hour into the trading day, the stock has already seen a volume of 1,205,322 shares, which is a significant portion of its average daily vo
Immuneering Corporation (IMRX) is experiencing a decline in its stock price, down 7.19% to $2.58 as of 9:37 am on September 18, after opening at $2.66. The stock has seen a high of $2.66 and a low of $2.50 during today's trading session. Despite the recent positive momentum driven by promising efficacy data from its pancreatic cancer study, which had propelled the stock up by over 94% since September 13, IM